Roth Capital Initiates Buy On ContraFect; Sees 305% Upside For The Stock
In a research report issued today, Roth Capital analyst Joseph Pantginis initiated coverage on ContraFect Corporation (CFRX) with a Buy rating and a $14 price target, which represents a potential upside of 305% from where the stock is currently trading.
Pantginis noted, “We believe the current market cap of ContraFect does not reflect the disruptive nature of the technology, ability to address significant unmet medical need, while taking into account a higher risk premium associated with novel therapies.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -9.0% and a 34.0% success rate. Pantginis is ranked #3302 out of 3315 analysts.